Skye Bioscience ($SKYE) Misleading Clinical Expectations and Trial Outcome Case
$SKYE investors filed a claim against Skye Bioscience for allegedly overstating the efficacy and commercial potential of its obesity drug candidate nimacimab, and for failing to disclose known risks related to dosing and trial outcomes.
After the company reported topline Phase 2a results showing that nimacimab failed to meet its primary endpoint, $SKYE fell 60% on October 7, 2025.
$SKYE investors can join this case to be notified about potential recovery.
Skye Bioscience is a clinical-stage biopharmaceutical company developing therapies for metabolic disorders. Its lead product candidate, nimacimab, is a CB1 receptor-targeting antibody designed to treat obesity without central nervous system side effects. On August 15, 2024, Skye launched its 26-week Phase 2a trial, known as “CBeyond,” to evaluate the drug’s safety and efficacy in overweight or obese patients.
Throughout late 2024 and into 2025, Skye issued public updates highlighting the potential of nimacimab based on preclinical data. Executives cited weight-loss effects observed in animal studies and emphasized the drug’s novel mechanism of action, describing it as a differentiated treatment with significant commercial potential. The company also suggested that nimacimab could work in combination with existing GLP-1-based therapies.
On October 6, 2025, Skye reported topline Phase 2a results, revealing that the nimacimab monotherapy arm failed to meet its primary endpoint of achieving statistically significant weight loss compared to placebo. The company also disclosed lower-than-expected drug exposure, which raised questions about dosing adequacy. On the following day, October 7, 2025, $SKYE stock dropped 60%, reflecting investor reaction to the trial outcome.
It overstated the clinical and commercial prospects of nimacimab.
It failed to disclose known limitations in dosing and trial design.
It misled investors about the likelihood of achieving positive Phase 2a results.
Investors argue that Skye Bioscience presented an overly optimistic view of its lead drug candidate, which led to losses when the trial results failed to meet expectations.